PTC THERAPEUTICS, INC. — Director's Dealing 2019

Dec 26, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PTC THERAPEUTICS, INC. (PTCT)
CIK: 0001070081
Period of Report: 2019-12-23

Reporting Person: Souza Marcio (Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-12-23	Common Stock	S	6000	$48.322	Disposed	53035	Direct
2019-12-23	Common Stock	S	14814	$49.141	Disposed	38221	Direct
2019-12-23	Common Stock	M	30000	$12.53	Acquired	68221	Direct
2019-12-23	Common Stock	S	8729	$48.321	Disposed	59492	Direct
2019-12-23	Common Stock	S	21271	$49.14	Disposed	38221	Direct
2019-12-23	Common Stock	M	15881	$11.23	Acquired	54102	Direct
2019-12-23	Common Stock	S	8877	$48.58	Disposed	45225	Direct
2019-12-23	Common Stock	S	7004	$49.319	Disposed	38221	Direct
2019-12-23	Common Stock	M	30000	$18.01	Acquired	68221	Direct
2019-12-23	Common Stock	S	11332	$48.431	Disposed	56889	Direct
2019-12-23	Common Stock	S	18668	$49.19	Disposed	38221	Direct
2019-12-23	Common Stock	M	6250	$12.92	Acquired	11288	Indirect
2019-12-23	Common Stock	S	6250	$48.80	Disposed	5038	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-12-23	Stock Option (Right To Buy)	$12.53	M	30000	Disposed	2027-05-30	Common Stock (30000.0)	Direct
2019-12-23	Stock Option (Right To Buy)	$11.23	M	15881	Disposed	2027-01-02	Common Stock (15881.0)	Direct
2019-12-23	Stock Option (Right To Buy)	$18.01	M	30000	Disposed	2028-01-02	Common Stock (30000.0)	Direct
2019-12-23	Stock Option (Right To Buy)	$12.92	M	6250	Disposed	2027-05-17	Common Stock (6250.0)	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right To Buy)	$33.02	2029-01-21	Common Stock (112500.0)	112500	Direct
Stock Option (Right To Buy)	$33.02	2029-01-21	Common Stock (25000.0)	25000	Direct
Stock Option (Right To Buy)	$26.42	2024-07-31	Common Stock (30000.0)	30000	Direct
Stock Option (Right To Buy)	$51.0	2025-01-02	Common Stock (10525.0)	10525	Direct
Stock Option (Right To Buy)	$30.86	2026-01-03	Common Stock (16000.0)	16000	Direct
Stock Option (Right To Buy)	$12.64	2026-11-16	Common Stock (2000.0)	2000	Direct
Stock Option (Right To Buy)	$33.02	2029-01-21	Common Stock (6825.0)	6825	Indirect
Stock Option (Right To Buy)	$18.01	2028-01-02	Common Stock (2696.0)	2696	Indirect

Footnotes

F1: The Reporting Person's transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 19, 2019.

F2: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $47.75 to $48.72 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F3: Includes 371 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending June 30, 2019.

F4: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $48.77 to $49.65 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F5: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $47.77 to $48.72 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F6: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $48.02 to $49.01 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F7: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $49.03 to $49.65 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F8: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $47.82 to $48.82 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F9: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $48.82 to $49.68 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F10: The transactions of the Reporting Person's spouse reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on November 19, 2019.

F11: Currently exerciseable.

F12: This option was granted on January 3, 2017, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018.

F13: This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019.

F14: This option was granted on May 17, 2017, and vests over four years, with 25% of the shares underlying the option vesting on May 8, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on August 8, 2018.

F15: This option was granted on January 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 22, 2020.

F16: This option was granted on January 22, 2019 and vests over four years, with 50% of the shares underlying the option vesting on January 22, 2022, and the remaining 50% of the original number of shares underlying the option vesting on January 22, 2023.

F17: This option was granted on January 4, 2016 and vests over four years, with 25% of the shares underlying the option vested on January 4, 2017, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 4, 2017.

F18: This option was granted on November 17, 2016, and vests over four years, with 25% of the shares underlying the option vesting on November 17, 2017, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on February 17, 2018.